The online version of this article (doi:10.1186/s12888-017-1419-7) contains supplementary material, which is available to authorized users.
People with severe mental ill health are more likely to smoke than those in the general population. It is therefore important that effective smoking cessation strategies are used to help people with severe mental ill health to stop smoking. This study aims to assess the effectiveness and cost –effectiveness of smoking cessation and reduction strategies in adults with severe mental ill health in both inpatient and outpatient settings.
This is an update of a previous systematic review. Electronic databases were searched during September 2016 for randomised controlled trials comparing smoking cessation interventions to each other, usual care, or placebo. Data was extracted on biochemically-verified, self-reported smoking cessation (primary outcome), as well as on smoking reduction, body weight, psychiatric symptom, and adverse events (secondary outcomes).
We included 26 trials of pharmacological and/or behavioural interventions. Eight trials comparing bupropion to placebo were pooled showing that bupropion improved quit rates significantly in the medium and long term but not the short term (short term RR = 6.42 95% CI 0.82–50.07; medium term RR = 2.93 95% CI 1.61–5.34; long term RR = 3.04 95% CI 1.10–8.42). Five trials comparing varenicline to placebo showed that that the addition of varenicline improved quit rates significantly in the medium term (RR = 4.13 95% CI 1.36–12.53). The results from five trials of specialised smoking cessation programmes were pooled and showed no evidence of benefit in the medium (RR = 1.32 95% CI 0.85–2.06) or long term (RR = 1.33 95% CI 0.85–2.08). There was insufficient data to allowing pooling for all time points for varenicline and trials of specialist smoking cessation programmes. Trials suggest few adverse events although safety data were not always reported. Only one pilot study reported cost effectiveness data.
Bupropion and varenicline, which have been shown to be effective in the general population, also work for people with severe mental ill health and their use in patients with stable psychiatric conditions. Despite good evidence for the effectiveness of smoking cessation interventions for people with severe mental ill health, the percentage of people with severe mental ill health who smoke remains higher than that for the general population.
Additional file 1: Search strategy, Description: example search strategy. (DOCX 13 kb)12888_2017_1419_MOESM1_ESM.docx
Tam J, Warner KE, Meza R. Smoking and the Reduced Life Expectancy of Individuals With Serious Mental Illness. Am J Prev Med. 51(6):958–66.
Cheeseman H, Harker K. The Stolen Years. In: Action on Smoking and Health. London; 2016.
Royal College of Physicians, Royal College of Psychiatrists Council Report CR178: smoking and mental health, RCP, Editor. 2013: London.
National Institute for Clinical Excellence, NICE public health guidance 48, Smoking cessation in secondary care in acute, maternity and mental health services. 2013, London: NICE.
BMA. General Medical Services (GMS) contract Quality and Outcomes Framework (QOF), NHS. Editor. 2016/17;2016
Higgins JPT, A.D. Sterne JAC , Chapter 8: Assessing risk of bias in included studies, in Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011), G.S. Higgins JPT , editor. 2011, The Cochrane Collaboration.
Steinberg ML. Engaging smokers with schizophrenia in treatment for tobacco dependence: A brief motivational interviewing intervention. Diss Abstr Int: Sect B: The Sci and Eng. 2003;64(3-B):1508.
Williams JM, et al. Comparison of two intensities of tobacco dependence counseling in schizophrenia and schizoaffective disorder. J Subst Abus Treat. 2010;38(4):384–93. CrossRef
Smith RC, et al. Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. PLoS One. 2016;11(1)
Cahill K, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; doi: 10.1002/14651858.CD009329.pub2.
Hartmann-Boyce J, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2016;9:CD010216. PubMed
O'Brien B, et al. E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial. Tob Induc Dis. 2015;13:7. CrossRef
Aubin H-J, et al. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ: Br Med J. 2012;345
Schulz KF, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Br Med J. 2010:340.
- Smoking cessation in severe mental ill health: what works? an updated systematic review and meta-analysis
- BioMed Central
Neu im Fachgebiet Psychiatrie
Meistgelesene Bücher aus dem Fachgebiet